Skip to main content

Peer Review reports

From: Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study

Original Submission
27 Jun 2023 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
20 Jul 2023 Author responded Author comments - Laura C Coates
Resubmission - Version 3
20 Jul 2023 Submitted Manuscript version 3
28 Aug 2023 Reviewed Reviewer Report
28 Aug 2023 Reviewed Reviewer Report
18 Sep 2023 Author responded Author comments - Laura C Coates
Resubmission - Version 4
18 Sep 2023 Submitted Manuscript version 4
22 Sep 2023 Author responded Author comments - Laura C Coates
Resubmission - Version 5
22 Sep 2023 Submitted Manuscript version 5
29 Sep 2023 Author responded Author comments - Laura C Coates
Resubmission - Version 6
29 Sep 2023 Submitted Manuscript version 6
28 Dec 2023 Reviewed Reviewer Report - Simone Parisi
Resubmission - Version 7
Submitted Manuscript version 7
Publishing
18 Jan 2024 Editorially accepted
4 Feb 2024 Article published 10.1186/s41927-024-00375-w

You can find further information about peer review here.

Back to article page